Phosphoric Acid

Phosphoric Acid

SCHEMBL3852404

O=P(O)(O)O.OCCON(OCCO)OCCO

nearest known ligand 0.33

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

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

The experimentally established mechanism targets of Phosphoric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 5)

geneUniProtsupporting neighboursconfidence
TSHR P16473 1/20 0.33
MAPK1 P28482 1/20 0.33
MEN1 O00255 1/20 0.32
KMT2A Q03164 1/20 0.32
PPARD Q03181 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Phosphoric Acid SCHEMBL8181905 0.97 TSHR (0.32) TSHRMAPK1MEN1KMT2APPARD
Phosphoric Acid SCHEMBL5084492 0.97 TSHR (0.32) TSHRMAPK1MEN1KMT2APPARD
SCHEMBL30539 0.85 TSHR (0.44) TSHRMAPK1MEN1KMT2A
Fluoride SCHEMBL923685 0.82 TSHR (0.41) TSHRMAPK1MEN1KMT2A
Iodide SCHEMBL5874477 0.82 TSHR (0.41) TSHRMAPK1MEN1KMT2A
Methane SCHEMBL1001960 0.82 TSHR (0.41) TSHRMAPK1MEN1KMT2A
Water SCHEMBL1246621 0.82 TSHR (0.41) TSHRMAPK1MEN1KMT2A
Bromide SCHEMBL5874693 0.82 TSHR (0.41) TSHRMAPK1MEN1KMT2A
Ammonia Solution, Strong SCHEMBL5393633 0.82 TSHR (0.41) TSHRMAPK1MEN1KMT2A
Hydrochloric Acid SCHEMBL634629 0.82 TSHR (0.41) TSHRMAPK1MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11939521-B2 Reuse of hypersaline brine with ionic liquids SAUDI ARABIAN OIL COMPANY (SA) 2024-03-26 US disclosed
US-20240059958-A1 REUSE OF HYPERSALINE BRINE WITH IONIC LIQUIDS SAUDI ARABIAN OIL COMPANY (SA) 2024-02-22 US disclosed
WO-2024039814-A1 REUSE OF HYPERSALINE BRINE WITH IONIC LIQUIDS SAUDI ARABIAN OIL COMPANY (SA) 2024-02-22 WO disclosed
US-20140348959-A1 Formulations and Methods for Treating Ear Conditions PARTICLE SCIENCES, INC. 2014-11-27 US disclosed
WO-2013123249-A2 FORMULATIONS AND METHODS FOR TREATING EAR CONDITIONS PARTICLE SCIENCES, INC. (US) 2013-08-22 WO disclosed
EP-1928439-A4 METHODS FOR TREATMENT AND PREVENTION OF OTITIS MEDIA USING CHEMICAL PENETRATION ENHANCERS TO FACILITATE TRANSMEMBRANE DRUG DELIVERY INTO THE MIDDLE EAR PIEDMONT PHARMACEUTICALS LLC (US) 2009-04-29 EP disclosed
US-20080318918-A1 Methods for Treatment and Prevention of Otitis Media Using Nonionic Surfactants to Facilitate Transmembrane Drug Delivery into the Middle Ear PIEDMONT PHARMACEUTICALS LLC 2008-12-25 US disclosed
US-20080269187-A1 Methods for Treatment and Prevention of Otitis Media Using Chemical Penetration Enhancers to Facilitate Transmembrane Drug Delivery Into the Middle Ear PIEDMONT PHARMACEUTICALS LLC 2008-10-30 US disclosed
CN-101272807-A Methods for treatment and prevention of otitis media using nonionic surfactants to facilitate transmembrane drug delivery to the middle ear PIEDMONT PHARMACEUTICALS LLC (US) 2008-09-24 CN disclosed
EP-1784164-A4 METHODS FOR TRANSMEMBRANE TREATMENT AND PREVENTION OF OTITIS MEDIA PIEDMONT PHARMACEUTICALS LLC (US) 2008-07-09 EP disclosed
US-20070218050-A1 Methods for treatment and prevention of otitis media using chemical penetration enhancers to facilitate transmembrane drug delivery into the middle ear PIEDMONT PHARMACEUTICALS LLC 2007-09-20 US disclosed
EP-1784164-A2 METHODS FOR TRANSMEMBRANE TREATMENT AND PREVENTION OF OTITIS MEDIA Piedmont Pharmaceuticals, LLC (US) 2007-05-16 EP disclosed
WO-2007037874-A2 METHODS FOR TREATMENT AND PREVENTION OF OTITIS MEDIA USING CHEMICAL PENETRATION ENHANCERS TO FACILITATE TRANSMEMBRANE DRUG DELIVERY INTO THE MIDDLE EAR PIEDMONT PHARMACEUTICALS LLC (US) 2007-04-05 WO disclosed
WO-2007037886-A2 METHODS FOR TREATMENT AND PREVENTION OF OTITIS MEDIA USING NONIONIC SURFACTANTS TO FACILITATE TRANSMEMBRANE DRUG DELIVERY INTO THE MIDDLE EAR PIEDMONT PHARMACEUTICALS LLC (US) 2007-04-05 WO disclosed
US-7128976-B2 Composition for film formation, method of film formation, and silica-based film JSR CORPORATION (JP) 2006-10-31 US disclosed
WO-2006029074-A2 METHODS FOR TRANSMEMBRANE TREATMENT AND PREVENTION OF OTITIS MEDIA PIEDMONT PHARMACEUTICALS, LLC (US) 2006-03-16 WO disclosed
CN-1674870-A Liposomes containing biologically active compounds PIEDMONT PHARMACEUTICALS LLC (US) 2005-09-28 CN disclosed
US-20030235610-A1 Liposomes containing biologically active compounds PIEDMONT PHARMACEUTICALS, LLC 2003-12-25 US disclosed
US-20030091838-A1 Composition for film formation, method of film formation, and silica-based film JSR CORPORATION (JP) 2003-05-15 US disclosed
US-4250046-A POLYOXYALKYLENE GLYCOL PENNWALT CORPORATION (US) 1981-02-10 US disclosed